{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:16:49Z","timestamp":1772180209287,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015639","name":"Japan Cardiovascular Research Foundation","doi-asserted-by":"crossref","award":["176"],"award-info":[{"award-number":["176"]}],"id":[{"id":"10.13039\/100015639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00380-019-01484-0","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T15:02:21Z","timestamp":1566658941000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study"],"prefix":"10.1007","volume":"35","author":[{"name":"The MAGIC Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6280-8190","authenticated-orcid":false,"given":"Shinichiro","family":"Uchiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Origasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Hiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"1484_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"1484_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849\u20131860","journal-title":"Lancet"},{"key":"1484_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1001\/archinte.162.19.2197","volume":"162","author":"SM Weisman","year":"2002","unstructured":"Weisman SM, Graham DY (2002) Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162:2197\u20132202","journal-title":"Arch Intern Med"},{"key":"1484_CR4","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373\u20132383","journal-title":"N Engl J Med"},{"key":"1484_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","volume":"106","author":"TA Pearson","year":"2002","unstructured":"Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106:388\u2013391","journal-title":"Circulation"},{"key":"1484_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","volume":"136","author":"M Hayden","year":"2002","unstructured":"Hayden M, Pignone M, Phillips C, Mulrow C (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136:161\u2013172","journal-title":"Ann Intern Med"},{"key":"1484_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.7326\/M14-1281","volume":"162","author":"AP DeFilippis","year":"2015","unstructured":"DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ (2015) An Analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 162:266\u2013275","journal-title":"Ann Intern Med"},{"key":"1484_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10557-011-6328-2","volume":"25","author":"H Origasa","year":"2011","unstructured":"Origasa H, Goto S, Shimada K, Uchiyama S, Okada Y, Sugano K, Hiraishi H, Uemura N, Ikeda Y, MAGIC Investigators (2011) Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the Magic study. Cardiovasc Drugs Ther 25:551\u2013560","journal-title":"Cardiovasc Drugs Ther"},{"key":"1484_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s00535-013-0839-5","volume":"49","author":"N Uemura","year":"2014","unstructured":"Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y, MAGIC Study Group (2014) Risk factor profiles, drug usages, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol 49:814\u2013824","journal-title":"J Gastroenterol"},{"key":"1484_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"1484_CR11","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706\u20131717","journal-title":"N Engl J Med"},{"key":"1484_CR12","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.109.895342","volume":"121","author":"PB Berger","year":"2010","unstructured":"Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ, CHARISMA Investigators (2010) Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or high risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121:2575\u20132583","journal-title":"Circulation"},{"key":"1484_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SC Connolly","year":"2011","unstructured":"Connolly SC, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806\u2013817","journal-title":"N Engl J Med"},{"key":"1484_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","volume":"11","author":"HC Diener","year":"2012","unstructured":"Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S, AVERROES Steering Committee Investigators (2012) Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomized trial. Lancet Neurol 11:225\u2013231","journal-title":"Lancet Neurol"},{"key":"1484_CR15","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"1484_CR16","first-page":"CD011088","volume":"12","author":"L Robertson","year":"2017","unstructured":"Robertson L, Yeoh SE, Ramli A (2017) Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database Syst Rev. 12:CD011088","journal-title":"Cochrane Database Syst Rev."},{"key":"1484_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cpcardiol.2017.01.006","volume":"42","author":"CJ Lavie","year":"2017","unstructured":"Lavie CJ, Howden CW, Scheiman JS, Tursi JT (2017) Upper gastrointestinal toxicity with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol 42:146\u2013164","journal-title":"Curr Probl Cardiol"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-019-01484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-019-01484-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-019-01484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:21:33Z","timestamp":1598138493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-019-01484-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s00380-019-01484-0","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"15 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SU received honoraria for consultancy and lecture fees and participation in clinical trials from Bayer, Boehringer Ingelheim, Daiichi-Sanyo, Bristol-Myers Squibb, AstraZeneca and Astellas Amgen, and research grant from Japan Cardiovascular Research Foundation. SG received research grants from Sanofi, Ono, Bristol-Myer Squibb and Pfizer. KS received grants from AstraZeneca, Takeda, Astellas and Daiichi-Sankyo and also sat on advisory panels for AstraZeneca, and Takeda. All other authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all subjects before the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by an institutional review committee at each participating center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}